As of March 31, 2025, the company had cash and cash equivalents of $13.9 million, compared to $23.3 million as of December 31, 2024. The company believes its cash balance as of March 31, 2025, is adequate to fund its basic budgeted operations into the fourth quarter of 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB:
- CLRB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cellectar Biosciences announces plan to explore strategic alternatives
- Cellectar Biosciences Enhances CEO and COO Severance Benefits
- Cellectar Biosciences: Promising Future with FDA Clarity and Innovative Radiopharmaceutical Advancements
- Cellectar Biosciences Faces Financial and Legal Turmoil Amidst Restated Earnings